Biosimilar Antibodies

Setrusumab (BPS 804) is a fully human monoclonal antibody that specifically targets sclerostin, a protein involved in the negative regulation of bone formation. By inhibiting sclerostin, Setrusumab enhances bone formation and improves bone strength. This antibody is primarily utilized in research focused on Osteogenesis Imperfecta (OI) and various cancer models where bone density and strength are of interest. Setrusumab offers a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for disorders associated with compromised bone integrity.

Ecleralimab (CSJ-117; NVP-CSJ117) is a recombinant monoclonal antibody of the Fab-IgG1-λ2 subtype, specifically designed to target thymic stromal lymphopoietin (TSLP). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in its structure and function. Ecleralimab is utilized primarily in research focused on understanding TSLP's role in immune response and potential therapeutic interventions.

Tafasitamab (XmAb5574) is an Fc-engineered, humanized monoclonal antibody specifically designed to target the CD19 antigen on human B-cell surfaces. This antibody's modifications enhance its binding affinity and efficacy in engaging immune effector functions, making it a critical tool in research focused on B-cell related diseases and therapeutics.

BI-765063 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting SIRPα (CD172a). This antibody is comprised of an IgG4PE heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 144.36 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the modulation and study of SIRPα-mediated signaling pathways.

Torudokimab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-33 (IL-33). This antibody is constructed with a human IgG4SP heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.22 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended.

Relatlimab (BMS-986016) is a human monoclonal antibody targeting LAG-3, developed through the immunization of transgenic mice engineered to express human immunoglobulin miniloci, using recombinant LAG-3 protein. This antibody effectively inhibits the interaction between LAG-3 and MHC II with an IC50 of 0.67 nM, and between LAG-3 and FGL1 with an IC50 of 0.019 nM. It is primarily utilized in cancer research, providing a valuable tool for investigating the role of LAG-3 in tumor immune evasion and potential therapeutic interventions.

Nidanilimab (CAN04) is a fully humanized monoclonal antibody targeting IL1RAP, characterized by a high affinity with a dissociation constant (Kd) of 1.10 pM. This antibody effectively inhibits signaling pathways mediated by IL1α and IL1β, thereby enhancing immune system responses against tumor cells. Nidanilimab is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), offering significant potential for elucidating disease mechanisms and therapeutic interventions in these cancers.

Opugotamig is a chimeric antibody designed with a half-immunoglobulin G1 kappa (half-IG G1 -κ) framework and incorporates a single-chain variable fragment (scFv -κ-heavy) linked to the human IgG CH2 and CH3 domains. It specifically targets the folate receptor alpha (FOLR1), making it suitable for research into cellular processes mediated by this receptor, including studies on targeted drug delivery and cancer cell biology.

The Anti-oxLDL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target oxidized low-density lipoprotein (oxLDL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the role of oxLDL in atherosclerosis and other related cardiovascular diseases.

Dostarlimab (TSR-042) is a humanized monoclonal antibody targeting PD-1 (Programmed Death-1). This antibody exhibits high affinity binding to PD-1, effectively blocking its interaction with the ligands PD-L1 and PD-L2. The inhibition constants (IC50) are determined to be 1.8 nM for PD-L1 and 1.5 nM for PD-L2, respectively. Dostarlimab serves as a potent inhibitor in the modulation of immune responses, making it a valuable tool in immunotherapy research.

Tilatamig is a human monoclonal antibody of the IgG1 subtype that specifically targets both EGFR and MET receptors. This dual specificity enables it to interfere with key pathways involved in cellular proliferation and survival, making it a valuable tool for research in cancer biology where these receptors are implicated.

CM-24 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CEACAM1/CD66a. This antibody has a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. CM-24 is designed for use in various immunological assays to study the function and role of CEACAM1/CD66a in biological processes.

Bevacizumab is a humanized IgG1 monoclonal antibody that exhibits high-affinity binding to all isoforms of vascular endothelial growth factor A (VEGF-A). This targeted binding inhibits the interaction of VEGF-A with its receptors, thereby modulating angiogenesis.

Imeroprubart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets FCGRT. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), exhibiting a high binding affinity with a dissociation constant (Kd) of less than 10 pM. This antibody effectively inhibits the production of interleukin-17 (IL-17) induced by IL-23 in mouse splenocytes, demonstrating a half-maximal inhibitory concentration (IC50) of 2 pM. Risankizumab is primarily utilized in research focused on immunological and inflammatory disorders, including psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis, providing a valuable tool for understanding the pathophysiology and potential therapeutic interventions for these conditions.

Atinumab (NG-101) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets RTN4/NOGO, a protein implicated in the inhibition of neuronal growth and regeneration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 146.62 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

NI-0801 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL10/IP-10. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Rafivirumab (CR57) is a monoclonal antibody designed for the prophylaxis of rabies, demonstrating neutralizing potency against a wide range of rabies virus (RABV) variants. This antibody is particularly useful in research focused on the development of therapeutic antibody cocktails targeting diverse strains of RABV.

The Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human PD-L1, also known as B7-H1. This antibody has been developed for high specificity and affinity to PD-L1, an important immune checkpoint protein that plays a critical role in inhibiting the immune response, thereby enabling cancer cells to evade immune detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa Isotype Control, which serves as a non-reactive baseline to assess the specific binding of the Anti-PD-L1/B7-H1 Antibody in various assays. This product is ideal for research applications focusing on cancer immunology and immune checkpoint regulation.

The Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody specifically designed to target GPRC5D, a receptor expressed predominantly on multiple myeloma cells. This antibody serves as the targeting component of the antibody-drug conjugate (ADC) LM-305, utilized in targeted cancer therapy. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for researchers focusing on oncology and therapeutic antibody development.

Uprevstobart is a human IgG1 κ monoclonal antibody targeting NT5E. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-IL-12 p70 Antibody (20C2) is a chimeric rat IgG1, κ antibody specifically designed to target human IL-12 p70. For accurate experimental control, the recommended isotype control is Rat IgG1 kappa, Isotype Control. This antibody facilitates detailed study of IL-12 p70's role in immunological responses and its potential implications in inflammatory diseases.

The Anti-CSF1R/CD115 Antibody (2-4A5-4) is a chimeric monoclonal antibody derived from rat IgG1, κ, specifically designed to target human CSF1R/CD115. This antibody is ideal for investigating the biological functions and signaling pathways mediated by CSF1R/CD115. For accurate isotype control in experiments, it is recommended to use the Rat IgG1 kappa Isotype Control, ensuring specificity and consistency in antibody performance.

Bezlotoxumab is a human monoclonal antibody that targets Clostridium difficile toxin B. By binding to this toxin, Bezlotoxumab effectively prevents the associated damage to intestinal epithelial cells and the onset of colitis. This antibody serves as a crucial tool in the study of gastrointestinal diseases and therapeutic interventions for C. difficile infections.

Narlumosbart (JMT103) is a monoclonal antibody of the IgG4κ subtype designed to specifically target the receptor activator of nuclear factor-κB ligand (RANKL). This antibody is engineered to interact with RANKL, a critical mediator in the regulation of bone metabolism, immune interactions, and the development of lymphoid tissues. Narlumosbart is utilized primarily in research focused on bone diseases, immune system disorders, and cancer metastasis to bone.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody engineered to selectively neutralize transforming growth factor beta 1 (TGFβ1). This specificity makes it a valuable tool for researchers studying fibrosis, cancer progression, and other TGFβ1-related pathologies.

Ubletamig is a human IgG4 κ monoclonal antibody targeting MUC16. For experimental control purposes, it is recommended to use Human IgG4 kappa as an Isotype Control.

Coramitug is a human IgG1 κ monoclonal antibody targeting transthyretin (TTR). For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Ramucirumab is a recombinant human IgG1 monoclonal antibody specifically designed to target and antagonize vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to the extracellular domain of VEGFR-2, Ramucirumab effectively inhibits the interaction with its natural ligands, VEGF-A, VEGF-C, and VEGF-D. This blockade disrupts the downstream signaling pathways that promote angiogenesis, making Ramucirumab a potent angiogenesis inhibitor. It is primarily utilized in the clinical management of various solid tumors, leveraging its mechanism to impair tumor vascularization and growth.

Solrikitug is a human IgG1 κ monoclonal antibody targeting the cytokine receptor-like factor 2 (CRLF2). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Idactamab (INT-001) is an IgG1-κ monoclonal antibody demonstrating significant in vivo activity against a range of hematological malignancies. This antibody serves as a precursor for the synthesis of MEDI7247, a highly potent and specific antibody-drug conjugate (ADC) that targets ASCT2 (SLC1A5), offering therapeutic potential in oncology research.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 antibody targeting the serum amyloid P component (SAP), exhibiting potential anti-amyloid activity. This antibody facilitates the immunotherapeutic clearance of amyloid deposits. It is primarily utilized in the study of Amyloid light-chain (AL) amyloidosis, providing a valuable tool for research into the pathogenesis and treatment of this condition.

The Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a chimeric mouse monoclonal antibody of the IgG2a subclass, specifically designed to target human CD54, also known as ICAM-1. This antibody has been engineered for optimal binding specificity to ICAM-1, a critical molecule involved in inflammation and immune responses. For accurate experimental control, the recommended isotype control is Mouse IgG2a kappa, which serves as a non-reactive benchmark to help discern specific antibody interactions. This product is ideal for researchers studying cellular adhesion, immune response modulation, and ICAM-1 related pathways in various disease models.

IMMU-114 is a humanized monoclonal antibody targeting human leukocyte antigen-DR (HLA-DR). This antibody is designed to deplete antigen-presenting cells (APCs) and diminish the population of alloreactive T cells, making it a valuable tool for research in immunology and transplantation studies.

Felzartamab (MOR-202) is a human monoclonal antibody designed to specifically bind to CD38, a glycoprotein predominantly expressed on the surface of multiple myeloma cells. This antibody is utilized extensively in research focused on the pathophysiology and treatment strategies of multiple myeloma, offering a critical tool for investigating disease mechanisms and therapeutic interventions.

Vopikitug is a human monoclonal antibody of the IgG1-kappa isotype, specifically targeting the interleukin-2 receptor alpha subunit (IL-2RA), also known as TAC, p55, or CD25. This antibody exhibits antineoplastic activity, making it relevant for research in cancer immunotherapy and the modulation of immune responses.

Erfonrilimab (KN-046) is a bifunctional monoclonal antibody designed to simultaneously inhibit both PD-L1 and CTLA-4, two critical immune checkpoint proteins. This dual inhibition mechanism enhances the immune system's ability to recognize and destroy cancer cells, making it a promising therapeutic agent in oncology research. Erfonrilimab is specifically engineered for use in investigating the efficacy of combined checkpoint blockade in various cancer models.

Ingitamig is a bispecific antibody engineered to target TNFRSF17 and KLRK1. This dual-specificity is achieved through its (G1_L-κ)_(G1-scFvkh_L-κ) configuration, making it a versatile tool in the study of immune responses and potential therapeutic interventions.

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.

Igovomab is a monoclonal antibody specifically designed for imaging applications in ovarian cancer research. This antibody targets antigens associated with ovarian cancer, facilitating the detailed study of disease pathology and aiding in the development of targeted therapies. Igovomab is utilized primarily in diagnostic research settings to improve the visualization and characterization of ovarian cancer tissues.

Simaravibart (MAD-0004J08) is an IgG1κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it an essential tool for research focused on the mechanisms of SARS-CoV-2 infection and immune response.

The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized monoclonal antibody, expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CDH17, also known as Cadherin-17. This antibody is composed of an IgG1 heavy chain and a human kappa (huκ) light chain, with a molecular weight of approximately 149.12 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of Cadherin-17 in cellular adhesion processes and its implications in gastrointestinal tract diseases and cancers.

Surovatamig is a bispecific antibody engineered to target CD3D, CD3E, and CD19. This antibody features a (H-γ4_L-κ)_VH-G4(h-CH2-CH3) structure, designed to engage both T cells and B cells for enhanced therapeutic efficacy. Surovatamig is utilized primarily in research focused on the mechanisms of immune response and potential therapeutic applications in immunotherapy. This product is pivotal for studies involving cell signaling and activation in immune cells, making it a valuable tool for investigations into novel cancer treatments and autoimmune disease therapies.

Amivantamab (JNJ-61186372) is a bispecific human antibody targeting EGFR and MET receptors, designed for its potent anticancer immune activity. This therapeutic antibody functions by inhibiting ligand binding, thereby promoting the endocytosis and subsequent degradation of receptor-antibody complexes. Furthermore, Amivantamab facilitates Fc-dependent cytokinesis in macrophages and enhances antibody-dependent cellular cytotoxicity in natural killer cells, making it a valuable tool in cancer immunotherapy research.

Vobarilizumab (ALX-0061) is a humanized bispecific monoclonal antibody that targets both the interleukin-6 receptor (IL-6R) and human serum albumin (ALB) with a dissociation constant (Kd) of 0.19 pM. This antibody features distinct domains: one that binds to IL-6R and another that binds to human serum albumin. The dual specificity of Vobarilizumab allows for enhanced targeting and retention in the human body, making it a valuable tool in the study of inflammatory autoimmune conditions, including rheumatoid arthritis. This antibody's unique configuration and high affinity make it ideal for research applications focused on the pathogenesis and treatment strategies of such diseases.

Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-γ. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.

Aldastotug is a human monoclonal antibody of the IgG1κ isotype designed to specifically target SIGLEC15. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.